Treatment of Hypercholesterolaemia in South Asian Subjects (IRIS) - IRIS

Study identifier:4522US/0006

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A 6-week, Randomized,Open-Label, Comparative study to Evaluate the Efficacy and Safety of Rosuvastatin and Atorvastatin in the treatment of Hypercholesterolaemia in South Asian Subjects.

Medical condition

Hypercholesterolemia

Phase

Phase 3

Healthy volunteers

Study drug

Rosuvastatin, Atorvastatin

Sex

All

Actual Enrollment

2340

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Oct 2002

Primary Completion Date: -

Study Completion Date: 01 Mar 2005

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Experimental: 1 Rosuvastatin	-
Active Comparator: 2 Atorvastatin	-

"There is no result for the study"

Documents available

CSR-4522US-0006.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

null AstraZeneca Clinical Study Information

800-236-9933

information.center@astrazeneca.com

Contact Backup

null AstraZeneca Information, (Outside US)

001-800-236-9933

Investigators

Principal Investigator

Dr. Prashkrah Deedwania

Institute for Medical consultation, USA